Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-nitroquinoline-1-oxide** is a quinoline-derived synthetic small molecule, primarily used as a model chemical carcinogen and mutagen in research settings[1][5]. It induces DNA lesions, including bulky adducts, DNA strand breaks, oxidative lesions (notably 8-hydroxydeoxyguanosine), and DNA-protein crosslinks, through both direct covalent binding and the generation of reactive oxygen species (ROS) after metabolic activation[1][5][7]. Its carcinogenic activity is exploited in laboratory animals (commonly rodent oral cancer models) to mimic the effects of tobacco carcinogens and test interventions for cancer prevention and treatment[5]. The compound is not used clinically, but serves as a tool for studying DNA repair, mutagenesis, and carcinogenesis mechanisms[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-nitroquinoline-1-oxide.